IMCIVREE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(3 years from now) | |
| US8039435 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(10 years from now) | |
Imcivree is owned by Rhythm.
Imcivree contains Setmelanotide Acetate.
Imcivree has a total of 3 drug patents out of which 0 drug patents have expired.
Imcivree was authorised for market use on 25 November, 2020.
Imcivree is available in solution;subcutaneous dosage forms.
Drug patent challenges can be filed against Imcivree from 25 November, 2024.
The generics of Imcivree are possible to be released after 04 July, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-336) | Nov 25, 2027 |
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2025 |
| Orphan Drug Exclusivity(ODE-402) | Jun 16, 2029 |
| New Indication(I-892) | Jun 16, 2025 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: 25 November, 2024
Market Authorisation Date: 25 November, 2020
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
IMCIVREE family patents
